Overview

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Status:
Terminated

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of sunitinib when given together with irinotecan, fluorouracil, and leucovorin in treating patients with advanced stomach cancer or gastroesophageal cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborator:

Pfizer

Treatments:

Calcium
Camptothecin
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Sunitinib